Interferon therapy in Hodgkin's disease. A case report.
The treatment of a case of Hodgkin's disease (lymphocyte predominance, stage IV B) with exogenous i.m. interferon therapy is described. B symptoms disappeared, diseased nodes and pulmonary infiltrations decreased in size, and laboratory values normalized. Clinical improvement was associated with increased mitogenic responsiveness of the patient's lymphocytes towards various stimuli in vitro. After almost half a year's treatment tumour progression and a decreased mitogenic response were again observed. Interferon treatment was then abandoned and combined cytostatic courses were instituted. Partial remission was achieved after 6 months of cytostatic therapy, i.e. 1 year after the start of treatment.
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003208:Concanavalin A / Q000494:pharmacology; D004359:Drug Therapy, Combination; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D037102:Lectins / Q000494:pharmacology; D008213:Lymphocyte Activation / Q000187:drug effects; D008297:Male; D008934:Mitogens / Q000494:pharmacology
D000970:Antineoplastic Agents; D037102:Lectins; D008934:Mitogens; D003208:Concanavalin A; D007372:Interferons